Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China

Figures & data

Table 1 Demographic characteristics

Parameter	Patients (N=500)
Male/female, n (%)	217 (43.4)/283 (56.6)
Age, mean (range), years	51 (18–95)
18–30 years, n (%)	43 (8.6)
31–40 years, n (%)	84 (16.8)
41–50 years, n (%)	121 (24.2)
51–60 years, n (%)	144 (28.8)
61–70 years, n (%)	74 (14.8)
>70 years, n (%)	34 (6.8)
Location, n (%)
Tier 1 city: Beijing, Guangzhou, or Shanghai	280 (56.0)
Tier 2 city: Changsha, Chengdu, Fuzhou,	220 (44.0)
Hangzhou, or Nanjing
Medical insurance coverage, n (%)
Yes	425 (85.0)
No	75 (15.0)
Employment status, n (%)
Full-time employment	212 (42.4)
Retired	212 (42.4)
Other	76 (15.2)
Annual household income (RMB), n (%)
0–34,999	80 (16.0)
35,000–44,999	68 (13.6)
45,000–59,999	97 (19.4)
≥60,000	231 (46.2)
Not reported	24 (4.8)

Table 2 Glaucoma and treatment history

Parameter	Patients (N=500)
Time since diagnosis of glaucoma
Mean, months	27
Range, years	0.25–20.2
Duration of topical IOP-lowering medication use
Mean, months	26
Range, years	0.33–20.3
Preexisting regimen before initiation of BTFC therapy, n (%)
Monotherapy
β-blocker	160 (32.0)
Prostaglandin analog	107 (21.4)
Carbonic anhydrase inhibitor	99 (19.8)
α-adrenergic agonist	61 (12.2)
Miotic	18 (3.6)
Combination therapy with two medications	55 (11.0)
Duration of treatment with BTFC, n (%)
1 month	43 (8.8)
>1–2 months	314 (62.8)
>2–3 months	143 (28.6)

Abbreviations: BTFC, bimatoprost/timolol fixed combination; IOP, intraocular pressure.

Table 3 Pattern of BTFC use

Treatment pattern	Patients (N=500)
BTFC used alone, n (%)	328 (65.6)
BTFC used with concomitant therapy, n (%)	172 (34.4)
Carbonic anhydrase inhibitor	71 (14.2)
Prostaglandin analog	47 (9.4)
β-blocker	25 (5.0)
α-adrenergic agonist	23 (4.6)
Miotic	2 (0.4)
Carbonic anhydrase inhibitor plus α-adrenergic agonist	1 (0.2)
Carbonic anhydrase inhibitor plus β-blocker	2 (0.4)
Carbonic anhydrase inhibitor plus prostaglandin analog	1 (0.2)
BTFC replaced other medication in preexisting regimen, n (%)a	435 (87.0)
Replaced β-blocker	161 (32.2)
Replaced prostaglandin analog	104 (20.8)
Replaced carbonic anhydrase inhibitor	65 (13.0)
Replaced α-adrenergic agonist	57 (11.4)
Replaced miotic	18 (3.6)
Replaced two medications	30 (6.0)
BTFC added to preexisting regimen, n (%)	65 (13.0)
Added to carbonic anhydrase inhibitor	36 (7.2)
Added to α-adrenergic agonist	10 (2.0)
Added to prostaglandin analog	8 (1.6)
Added to β-blocker	6 (1.2)
Added to miotic	1 (0.2)
Added to two medications	4 (0.8)

Note:

a Patients who used BTFC in replacement of one or two medications may have had other ongoing medication.

Abbreviation: BTFC, bimatoprost/timolol fixed combination.

Table 4 Reasons for initiating BTFC therapy

Reason, n (%)a	Total patient population (N=500)	Subgroup based on previous regimen
		β-blocker (N=160)	Prostaglandin analog (N=107)	Carbonic anhydrase inhibitor (N=99)	α-adrenergic agonist (N=61)	Miotic (N=18)	Two drugs (N=55)
Poor efficacy of previous medication(s)b	336 (67.2)	110 (68.8)	65 (60.7)	71 (71.1)	61 (100)	18 (100)	37 (67.3)
Safety profile/side effect of previous medication(s)b	154 (30.8)	50 (31.3)	31 (29.0)	23 (23.2)	16 (26.2)	12 (66.7)	22 (40.0)
BTFC recommended by friend/family/other patientb	155 (31.0)	63 (39.4)	32 (29.9)	24 (24.2)	16 (26.2)	4 (22.2)	16 (29.1)
Inconvenient administration of previous medication(s)b	100 (20.0)	44 (27.5)	21 (19.6)	8 (8.1)	14 (23.0)	2 (11.1)	11 (20.0)
Patient’s desire to try BTFCb	90 (18.0)	39 (24.4)	13 (12.1)	16 (16.2)	12 (19.7)	4 (22.2)	6 (10.9)
Cost of previous medication(s)b	29 (5.8)	8 (5.0)	14 (13.1)	1 (1.0)	2 (3.3)	0 (0)	4 (7.3)
Physician recommendationb	13 (2.6)	6 (3.8)	5 (4.7)	1 (1.0)	0 (0)	0 (0)	1 (1.8)
Better control of IOP with BTFCc	20 (4.0)	9 (5.6)	1 (0.9)	4 (4.0)	3 (4.9)	1 (5.6)	2 (3.6)
Simple administration of BTFCc	11 (2.2)	5 (3.1)	1 (0.9)	4 (4.0)	1 (1.6)	1 (5.6)	2 (3.6)
Fewer side effects with BTFCc	12 (2.4)	8 (5.0)	0 (0)	3 (3.0)	0 (0)	0 (0)	1 (1.8)
BTFC used before or after surgeryc	4 (0.8)	1 (0.6)	1 (0.9)	1 (1.0)	1 (1.6)	0 (0)	0 (0)
BTFC used for consolidationc	1 (0.2)	1 (0.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Notes:

a Patients could provide more than one reason for initiating BTFC treatment.

b Selected response.

c Volunteered response.

Abbreviations: BTFC, bimatoprost/timolol fixed combination; IOP, intraocular pressure.

Table 5 Mean BTFC and previous treatment satisfaction scores in all patients and subgroups based on treatment parameters

Patient group	N	Mean satisfaction score (SD)		P-valuea
		BTFC	Previous treatment
Total patient population	500	7.8 (1.6)	6.0 (1.5)	<0.0001
Subgroups by pattern of BTFC use
Treated with BTFC alone	325	7.9 (1.4)	6.0 (1.5)	<0.0001
Treated with BTFC and other therapy	175	7.6 (1.9)	6.2 (1.5)	<0.0001
BTFC replaced other drug(s)	435	8.0 (1.4)	6.0 (1.5)	<0.0001
BTFC added to previous treatment	65	6.8 (2.3)	6.3 (1.8)	0.0433
Subgroups by previous treatment
β-blocker	160	7.9 (1.2)	5.8 (1.3)	<0.0001
Prostaglandin analog	107	8.1 (1.4)	6.2 (1.5)	<0.0001
Carbonic anhydrase inhibitor	99	7.5 (1.6)	6.0 (1.6)	<0.0001
α-adrenergic agonist	61	7.7 (1.9)	6.1 (1.6)	<0.0001
Miotic	18	9.1 (1.5)	6.5 (1.4)	<0.0001
Two drugs	55	7.3 (2.1)	6.3 (1.5)	0.0051
Subgroups by reason for initiating BTFC
Poor efficacy of previous treatment	336	7.7 (1.7)	6.0 (1.5)	<0.0001
Side effect of previous treatment	154	7.8 (1.6)	5.9 (1.5)	<0.0001
BTFC recommended by friend/family/other patient	155	8.0 (1.3)	6.0 (1.3)	<0.0001
Inconvenient administration of previous treatment	100	7.9 (1.4)	5.8 (1.3)	<0.0001
Patient desire to try BTFC	90	8.2 (1.2)	6.1 (1.4)	<0.0001
Subgroups by duration of BTFC treatment
1 month	43	7.5 (1.4)	5.8 (1.5)	<0.0001
>1–2 months	314	7.8 (1.7)	5.9 (1.5)	<0.0001
>2–3 months	143	7.9 (1.6)	6.4 (1.6)	<0.0001

Note:

a The P-value for comparison between BTFC and previous treatment (paired t-test).

Abbreviations: BTFC, fixed-combination bimatoprost/timolol; SD, standard deviation.

Table 6 Mean BTFC and previous treatment satisfaction scores in patient subgroups based on demographics

Demographic parameter	Patient subgroup	N	Mean satisfaction score (SD)		P-valuea
			BTFC	Previous treatment
Gender	Male	217	8.0 (1.6)	6.0 (1.4)	<0.0001
	Female	283	7.7 (1.6)	6.1 (1.5)	<0.0001
Age	18–30 years	43	7.1 (1.8)	5.4 (1.7)	<0.0001
	31–40 years	84	7.8 (1.8)	6.2 (1.6)	<0.0001
	41–50 years	121	7.9 (1.6)	6.2 (1.4)	<0.0001
	51–60 years	144	7.8 (1.5)	6.0 (1.4)	<0.0001
	61–70 years	74	8.2 (1.3)	6.1 (1.6)	<0.0001
	>70 years	34	7.7 (1.6)	6.2 (1.4)	<0.0001
Medical insurance coverage	Yes	425	7.9 (1.6)	6.1 (1.4)	<0.0011
	No	75	7.4 (1.8)	5.7 (1.8)	<0.0011
Employment	Full-time worker	212	7.8 (1.7)	6.1 (1.5)	<0.0001
	Retired	212	7.9 (1.4)	6.1 (1.4)	<0.0001
	Other	76	7.5 (1.8)	5.7 (1.6)	<0.0001
Annual household income (RMB)	<14,000	19	8.1 (1.8)	7.0 (1.5)	0.0481
	14,001–19,999	10	8.1 (1.1)	5.3 (1.0)	<0.0001
	20,000–24,999	14	7.8 (1.8)	5.7 (1.1)	0.0009
	25,000–34,999	37	7.8 (1.6)	6.1 (1.6)	<0.0001
	35,000–44,999	68	7.6 (1.8)	5.9 (1.4)	<0.0001
	45,000–59,999	97	7.9 (1.5)	6.0 (1.5)	<0.0001
	≥60,000	231	7.9 (1.5)	6.2 (1.4)	<0.0001
	Unknown	24	7.3 (2.3)	5.3 (1.8)	0.0002

Note:

a The P-value for comparison between BTFC and previous treatment (paired t-test).

Abbreviations: BTFC, fixed-combination bimatoprost/timolol; SD, standard deviation.

Figure 1 Percentage of patients who agreed or strongly agreed with statements regarding IOP control, ease of use, and tolerability of BTFC compared with previous treatment.

Abbreviations: BTFC, bimatoprost/timolol fixed combination; IOP, intraocular pressure.